05:00 PM - 06:00 PM (Pacific)
06:00 PM - 07:00 PM (Mountain)
07:00 PM - 08:00 PM (Central)
08:00 PM - 09:00 PM (Eastern)
Zoom Invitation Will Be Shared the Day Before the Event
General principles of what makes a good director will be discussed, including
- How to foster a good working relationship between the board and management
- Adequately fulfilling fiduciary duties and obligations
- Appropriate board governance structures at various stages of a company’s life cycle and how a director’s role might change as a company goes from private to public
- What a good director does to support the company in that transformation
- How to recruit good people to the board
- How to do this virtually in this new world and how things may have already changed this year due to COVID-19
THANK YOU TO OUR NATIONAL AND GOLD CHAPTER SPONSORS!
Douglas Crawford is the Managing Partner of Mission BioCapital and has overseen investment in 52 companies, 11 of which have already enjoyed successful liquidity events (Alector, Atreca, Calithera, Cell Design Labs, iPierian, Pionyr, Principia, Redwood Biosciences, True North, Vedere, and Zephyrus). He is a board member of Avexegen, Alessa, Epiodyne, Graphwear, Invenio, Magnamosis, Magnap, Mitokinin, SiteOne (observer), and Tangible Sciences. Doug’s goal is to help entrepreneurial scientists create successful startups and to this end, he has helped systematically lower the barriers between great ideas and successful companies. He created and manages MBC BioLabs, a state-of-the-art co-working laboratory network in San Francisco and San Carlos.
David Earp, J.D., Ph.D.
President & CEO
David Earp, J.D., Ph.D., has served as the President & CEO of Circle Pharma since October 2013. Previously, David held various roles at Geron Corporation (GERN), including chief patent counsel, chief legal officer and senior vice president of corporate transactions, building a broad IP portfolio and playing an integral role in numerous partnering, licensing and collaboration deals. He led the spin-out of Geron’s nuclear transfer technology to StART and its subsequent acquisition by Viagen Corp., serving on the boards of StART and Viagen, including as executive chairman of Viagen in which capacity he led the sale of the company to TransOva Genetics (subsequently acquired by Intrexon). David was also a member of the board of directors of TA Therapeutics Ltd. (Hong Kong, PRC) and Sienna Cancer Diagnostics (Melbourne, Australia).
Independent Board Director
Penny Herscher serves on four public company boards: Lumentum, Faurecia SA, PROS and Verint Systems and two private company boards, Delphix and Modern Health. She was President & CEO of two technology companies, Simplex and FirstRain, over the last 20 years. She is an experienced technology CEO, based in Silicon Valley, who took her first company, Simplex Solutions, public and then sold it to Cadence Design Systems in 2002. She sold her second company, FirstRain, to Ignite Technologies in 2017. Prior to Simplex, Penny was a member of the executive leadership team at Synopsys, through the IPO, on the way to becoming the #1 EDA company.
Wilson Sonsini Goodrich & Rosati
Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. He specializes in public and private corporate finance and corporate law and governance. Elton also has considerable expertise in the areas of mergers and acquisitions and venture capital. Elton serves as co-editor of The Life Sciences Report, a semi-annual newsletter on the life sciences industry published by the firm. He received an LL.B. from Osgoode Hall Law School, Toronto, in 1996.